logo-loader

NanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst

Last updated: 14:15 12 Jul 2023 EDT, First published: 14:08 12 Jul 2023 EDT

Proactive research analyst John Savin speaks to Thomas Warner after releasing a new report on NanoViricides (NYSE-A:NNVC), a development-stage company that is creating special-purpose nanomaterials for antiviral therapy.

Savin gives an overview of what the company does, as well as its current operations and its financial situation.

He highlights that NanoViricides is currently undertaking its first ever clinical trial, of an edible treatment for Covid-19 in India.

Click here to read the report

NanoViricides unimpacted by tariffs; sees boost by changes at government...

NanoViricides Chief Financial Officer Meeta Vyas joined Steve Darling from Proactive to share updates on the company’s development of broad-spectrum antiviral therapeutics and its unique positioning amid global market uncertainty. Vyas emphasized that NanoViricides, headquartered in Shelton,...

on 4/4/25
OSZAR »